Archives of Obesity and Metabolism (비만대사연구학술지)

The Study of Obesity and Metabolic Syndrome, KAFM (대한가정의학회 비만대사증후군연구회)
권호 표지
DOI QR코드

DOI QR Code

Case of Effective Treatment using Glucagon-Like Peptide-1 Receptor Agonist in Patient with Obesity and Non-Alcoholic Fatty Liver Disease

비알코올지방간질환을 동반한 비만 환자에서 Glucagon-Like Peptide-1 수용체작용제를 이용한 효과적인 치료 증례

  • Tae Sic Lee (Department of Family Medicine, Wonju Severance Christian Hospital, Yonsei University Wonju College of Medicine)
  • 이태식 (연세대학교 원주의과대학 원주세브란스기독병원 가정의학과)
  • Received : 2023.09.29
  • Accepted : 2023.12.06
  • Published : 2023.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

Obesity is closely related to chronic diseases and cancer. The present case report aims to discuss the anti-obesity treatment strategy and the evaluation of the clinical progress in a patient with obesity and concurrent fatty liver disease. Following five months of treatment with liraglutide and rosuvastatin, the patient had a weight reduction of 3 kg (4.7%), a decrease in fasting blood sugar by 42 mg/dl (26.6%), a decrease in low-density lipoprotein cholesterol by 82 mg/dl (60.2%), and decrease in alanine transaminase. This case report documented the treatment of a patient with common chronic diseases encountered in the outpatient setting. Based on the therapeutic effects documented in clinical and laboratory indices, the anti-obesity treatment plan significantly aided in managing chronic diseases.

Keywords

Acknowledgement

The Figure (Figure 2 in manuscript) used for the current case described in this manuscript were obtained from: the GTEx Portal on 08/16/2023.

References

  1. Finucane MM, Stevens GA, Cowan MJ, et al. National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. Lancet 2011;377:557-67. https://doi.org/10.1016/S0140-6736(10)62037-5
  2. Global BMI Mortality Collaboration, Di Angelantonio E, Bhupathiraju ShN, et al. Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents. Lancet 2016;388:776-86. https://doi.org/10.1016/S0140-6736(16)30175-1
  3. Li L, Liu DW, Yan HY, Wang ZY, Zhao SH, Wang B. Obesity is an independent risk factor for non-alcoholic fatty liver disease: evidence from a meta-analysis of 21 cohort studies. Obes Rev 2016;17:510-9. https://doi.org/10.1111/obr.12407
  4. Lee JH, Kim D, Kim HJ, et al. Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease. Dig Liver Dis 2010;42:503-8. https://doi.org/10.1016/j.dld.2009.08.002
  5. Lee T, Chung TH. Comparative analysis of the relationship between four hepatic steatosis indices and muscle mass. Sci Rep 2023;13:1645.
  6. GTEx Consortium. The Genotype-Tissue Expression (GTEx) project. Nat Genet 2013;45:580-5. https://doi.org/10.1038/ng.2653
  7. Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology 2015;149:367-78.e5; quiz e14-5. https://doi.org/10.1053/j.gastro.2015.04.005
  8. Koutoukidis DA, Jebb SA, Zimmerman M, et al. The association of weight loss with changes in the gut microbiota diversity, composition, and intestinal permeability: a systematic review and meta-analysis. Gut Microbes 2022;14:2020068.
  9. Wang M, Li L, Xu Y, Du J, Ling C. Roles of hepatic stellate cells in NAFLD: From the perspective of inflammation and fibrosis. Front Pharmacol 2022;13:958428.
  10. Petit JM, Cercueil JP, Loffroy R, et al. Effect of liraglutide therapy on liver fat content in patients with inadequately controlled Type 2 diabetes: the Lira-NAFLD study. J Clin Endocrinol Metab 2017;102:407-15.
  11. Duparc T, Briand F, Trenteseaux C, et al. Liraglutide improves hepatic steatosis and metabolic dysfunctions in a 3-week dietary mouse model of nonalcoholic steatohepatitis. Am J Physiol Gastrointest Liver Physiol 2019;317:G508-17. https://doi.org/10.1152/ajpgi.00139.2019
  12. Zhu H, Zhang Y, Shi Z, et al. The neuroprotection of liraglutide against ischaemia-induced apoptosis through the activation of the PI3K/AKT and MAPK pathways. Sci Rep 2016;6:26859.
  13. Ripa RS, Zobel EH, von Scholten BJ, et al. Effect of liraglutide on arterial inflammation assessed as [18F]FDG uptake in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial. Circ Cardiovasc Imaging 2021;14:e012174.
  14. Smits MM, Tonneijck L, Muskiet MH, et al. Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial. Diabetologia 2016;59:2588-93. https://doi.org/10.1007/s00125-016-4100-7
  15. Newsome PN, Buchholtz K, Cusi K, et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med 2021;384:1113-24. https://doi.org/10.1056/NEJMoa2028395
  16. Loomba R, Abdelmalek MF, Armstrong MJ, et al. Semaglutide 2.4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial. Lancet Gastroenterol Hepatol 2023;8:511-22. https://doi.org/10.1016/S2468-1253(23)00068-7
  17. Luvai A, Mbagaya W, Hall AS, Barth JH. Rosuvastatin: a review of the pharmacology and clinical effectiveness in cardiovascular disease. Clin Med Insights Cardiol 2012;6:17-33. https://doi.org/10.4137/CMC.S4324
  18. Klop B, Elte JW, Cabezas MC. Dyslipidemia in obesity: mechanisms and potential targets. Nutrients 2013;5:1218-40. https://doi.org/10.3390/nu5041218
  19. Kim KK. Peptides in obesity treatment. Arch Obes Metab 2022;1:4-13.
  20. Wang Y, Perfetti R, Greig NH, et al. Glucagon-like peptide-1 can reverse the age-related decline in glucose tolerance in rats. J Clin Invest 1997;99:2883-9. https://doi.org/10.1172/JCI119482
  21. Farilla L, Bulotta A, Hirshberg B, et al. Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology 2003;144:5149-58. https://doi.org/10.1210/en.2003-0323
  22. Romani-Perez M, Outeirino-Iglesias V, Gil-Lozano M, Gonzalez-Matias LC, Mallo F, Vigo E. Pulmonary GLP-1 receptor increases at birth and exogenous GLP-1 receptor agonists augmented surfactant-protein levels in litters from normal and nitrofen-treated pregnant rats. Endocrinology 2013;154:1144-55. https://doi.org/10.1210/en.2012-1786
  23. Baggio LL, Drucker DJ. Glucagon-like peptide-1 receptors in the brain: controlling food intake and body weight. J Clin Invest 2014;124:4223-6. https://doi.org/10.1172/JCI78371
  24. Hunter GR, Plaisance EP, Fisher G. Weight loss and bone mineral density. Curr Opin Endocrinol Diabetes Obes 2014;21:358-62. https://doi.org/10.1097/MED.0000000000000087
  25. Said MA, Abdelmoneem M, Almaqhawi A, Hamid Kotob AA, Alibrahim MC, Bougmiza I. Multidisciplinary approach to obesity: aerobic or resistance physical exercise? J Exerc Sci Fit 2018;16:118-23. https://doi.org/10.1016/j.jesf.2018.11.001
  26. Bischoff SC, Boirie Y, Cederholm T, et al. Towards a multidisciplinary approach to understand and manage obesity and related diseases. Clin Nutr 2017;36:917-38. https://doi.org/10.1016/j.clnu.2016.11.007